FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to a method for determining a risk of ischemic heart disease by the biochemical blood serum count to determine malondialdehyde, nitrogen oxide, phospholipase A2 and endotoxin; if observing an increase of the malondialdehyde level to 14.8 mcmole/l and more, the nitrogen oxide level to 122.3 mcmole/l and more, the phospholipase A2 level to 402.5 ng/ml and more, and the endotoxin level to 3.1 EU/ml and more, the risk of ischemic heart disease is stated.
EFFECT: method provides the more accurate determination of the risk of ischemic heart disease.
2 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR HEPATIC STEATOSIS AND STEATOHEPATITIS | 2013 |
|
RU2545990C2 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2013 |
|
RU2537229C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS | 2018 |
|
RU2706026C1 |
| METHOD OF TREATING CHRONIC CONSTIPATION AND FUNCTIONAL ANOREXIA | 2013 |
|
RU2545988C1 |
| METHOD FOR ENDOSCOPIC DISSECTION OF EPITHELIAL FORMATIONS OF THE DIGESTIVE TRACT | 2022 |
|
RU2790240C1 |
| METHOD FOR ASSESSING EFFICACY OF NUTRITIONAL SUPPORT ACCOMPANYING ULCERATIVE COLITIS | 2013 |
|
RU2552319C1 |
| DIAGNOSTIC TECHNIQUE FOR ASYMPTOMATIC CELIAC DISEASE IN ADULTS | 2020 |
|
RU2747523C1 |
| METHOD OF LACTASE DEFICIENCY IN ADULTS TREATMENT | 2017 |
|
RU2684099C1 |
| METHOD OF THE TREATMENT OF POLYNEUROPATHY ASSOCIATED WITH GLUTEN-SENSITIVE CELIAC DISEASE | 2022 |
|
RU2800847C1 |
| METHOD FOR ASSESSING CLINICAL EFFECTIVENESS IN IRRITABLE BOWEL SYNDROME ACCOMPANIED BY DIARRHOEA | 2014 |
|
RU2570767C1 |
